Compare Aehr Test Systems (AEHR) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aehr Test Systems vs BridgeBio Pharma Inc — how do they compare? Aehr Test Systems trades at $124 (market cap $3.82B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B). The key difference: BridgeBio Pharma Inc is far larger — about 4.3× Aehr Test Systems's market cap, and Aehr Test Systems is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| AEHR | BBIO | |
|---|---|---|
Market Cap | $3.82B | $16.36B |
Sector | Technology | Health |
52-Week High | $117.18 | $90.17 |
52-Week Low | $17.38 | $47.29 |
Enterprise Value | $3.72B | $18.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aehr Test Systems
Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.
Read more on AEHR →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
